Gujarat Themis Biosyn Limited has informed the Exchange regarding a press release dated May 22, 2026, titled "Press Release dated 22nd May, 2026".
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GTBL has signed a definitive agreement to acquire 100% equity stake in MicroBiopharm Japan Co., Ltd. (MBJ) from T Capital Partners for approximately JPY 21.5 billion (around INR 1,300 crores). MBJ is a Japanese pharmaceutical company with over 60 years of experience in fermentation-based R&D and manufacturing, including proprietary pharmaceuticals in oncology, immunosuppressants, antibiotics, and peptides. MBJ also provides CDMO services in small molecules and biologics, with estimated revenue of JPY 9.5 billion (approximately INR 570 crores) for FY26E. About 47% of MBJ's revenue comes from proprietary pharmaceuticals and non-pharma products, with ~40% from overseas markets. Two of MBJ's three Japanese manufacturing sites have FDA and PMDA audit track records. The acquisition will be funded through a mix of debt and equity, expected to close in Q2FY27.
This acquisition positions GTBL as a globally integrated CDMO platform with access to advanced fermentation technologies, high-margin biologics capabilities (ADC, plasmid DNA), and established regulatory credentials in regulated markets. It is expected to be EPS accretive and significantly expands GTBL's revenue base and geographic reach.